MedTrace Logo

Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception

NCT03614494 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 860

Last updated 2024-05-06

Study results available
· View outcomes & findings →

Summary

This is a randomised controlled trial aimed at comparing the efficacy of levonorgestrel (LNG) co-administered with piroxicam or placebo for oral emergency contraception (EC). Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a pain-killer in inflammatory conditions. Efficacy will be measured as the percentage of pregnancies prevented.

Conditions

  • Emergency Contraception

Interventions

DRUG

Piroxicam 40 mg

Additional co-treatment

DRUG

Levonorgestrel 1.5mg

Standard treatment

Sponsors & Collaborators

  • The Family Planning Association of Hong Kong

    collaborator OTHER

  • Dr. Hang Wun Raymond Li

    lead OTHER

Principal Investigators

  • Hang Wun Raymond Li, MD, FRCOG · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2022-10-05
Completion
2022-10-05

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03614494 on ClinicalTrials.gov